Cohance Lifesciences Limited (COHANCE) showcased a clear sequential recovery in its Q2 FY27 investor presentation, with revenue up 13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1. The integrated capabilities of One Cohance are strengthening the growth platform.

Strategic Progress

The integration of One Cohance is driving operational and commercial progress across businesses. In the Pharma CDMO segment, the order and reload position for Q3 and Q4 has improved materially. Cohance secured two new commercial and one late-stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities. In the nucleic acid business, Sapala’s strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance’s development and manufacturing network.

Financial Performance

API+ revenue grew year-on-year, supported by selective pricing actions, while lower API volumes, shipment phasing, and higher raw-material costs impacted margins. Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure, and programme phasing, while Performance Materials remained relatively stable. The company plans to announce investments in capex towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform.

Looking Ahead

H2 FY27 revenue and EBITDA are expected to grow year-on-year, supported by continued recovery and progressive integration of Cohance’s capabilities to unlock platform potential. The H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 30% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. The stock rises 5.0% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.

Cohance Lifesciences Limited (COHANCE) announced two proposed transactions on September 3, 2026, to strengthen its Antibody-drug Conjugate (ADC) strategy. The company plans to invest USD 13 million in NJ Bio and USD 5 million in Aruka Bio. Both transactions will be funded through internal accruals. This reorganization aims to deepen the integration of NJ Bio’s customer-facing services with Cohance and focus on developing Aruka’s proprietary pipeline through potential partnerships.

NJ Bio: Increased Ownership and Integration

Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%. Dr. Jain will continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives. NJ Bio will remain focused on customer-facing contract research, development, and manufacturing services. The closer integration will combine its payload-linker and bioconjugation expertise with Cohance’s manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.

Aruka Bio: Control and Development

Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Cohance’s USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital. Following completion, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio, and 10% by Dr. Jain. Aruka will become Cohance’s direct subsidiary. The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing, and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.

Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said, “This reorganization gives each business a clear focus: strengthening NJ Bio’s customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka’s next phase. This integration is expected to strengthen business performance across the combined platform over time.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 4.2x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 6.9% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.

Cohance Lifesciences Limited (COHANCE) breaks out, gaining +5% to ₹470.8 on the NSE on 11 Aug 2026. The stock cleared its 6M resistance trendline, transitioning from a bounce from support to a breakout. Cohance operates in the healthcare sector, specifically in specialty and generic drug manufacturing. Today’s move appears to be company-specific, driven by technical factors rather than broader sector momentum.

Technical setup — trendlines & DMA

The current 6M trendline structure shows a breakout above the resistance at ₹429.16, with the stock now trading 8.84% above this level. The 6M support trendline ends at ₹431.05, which is 8.44% below today’s price. The 50-DMA at ₹435.7 is slightly above the 200-DMA at ₹434.1, indicating a bullish trend. The stock is currently in the lower third of its 52W range of ₹266.7–₹1038.9, suggesting there may be room for further upside despite the recent breakout.

Fundamentals & business context

With a PE of 162.0 and profit margins at 5.0%, Cohance’s valuation appears stretched relative to its current earnings, especially given the revenue CAGR of 19.4%. The market may be pricing in a potential turnaround, but the declining profit CAGR of -24.2% over the past five years raises concerns. Institutional ownership stands at 23.3%, indicating some level of confidence from smart money, though the lack of recent NSE filings suggests the move is driven by technical factors rather than new fundamental information.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile. The strongest signals include the bullish trend indicated by the 50-DMA being above the 200-DMA and the bullish sentiment over the last 30 days, where up days saw significantly higher volume than down days. These factors suggest systematic accumulation and positive market sentiment. However, the weakest signals are the low profit margin of 5.0% and the negligible dividend yield of 0%, which highlight the company’s thin profits and lack of income generation for shareholders. Additionally, the company reported a loss in the last quarter, adding to the caution.

Company outlook

Cohance Lifesciences is currently navigating through a challenging phase with low revenue and EBITDA expected in Q1 FY27 due to skewed revenue schedules, increased logistics and input costs, and higher operating costs. However, the company anticipates an improvement in EBITDA in the second half of the year as volumes recover and order conversion improves. The business is expected to bottom out in Q1 FY27, with recovery becoming more visible from the second half of FY27.

Management expects Q1 FY27 to be the low point for both revenue and EBITDA, with improvement becoming visible in the second half of the year. Growth is anticipated to return from the second half of FY27 onwards, with Q2 being stable and H2 showing growth. The company plans to focus on the predictability of delivery, backed by strong quality and systems, and is progressing with a $10 million capex at the NJ Bio US facility to support future scale-up and validation readiness. Additionally, Cohance expects to spend nearly INR 3 billion in capex in FY27.

Get all details on COHANCE — P&L, peers, shareholding and more on TradeAlone.